A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
Active, not recruiting · Phase 2 · NCT05683457
Conditions: Cytomegalovirus Infection
At a glance
- Research payments reported, 2025
- $476,474
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 84
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1647 (biological), Placebo (biological)
- Dates
- Started 2023-04-05; completion 2027-03-06
- Results posted
- Not yet
The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 post-HCT through Month 9 post-HCT.
From ClinicalTrials.gov, last updated 2026-08-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $476,474 in research payments for this study in 2025 (24 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nicolas C. Issa, MD Infectious Disease · Boston, MA
- Adriana M. Rauseo Acevedo, MD Infectious Disease · Saint Louis, MO
- Michael J. Boeckh, MD Infectious Disease · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber Cancer Institute Inc $431,310
- Fred Hutchinson Cancer Center $26,085
- The Washington University $19,079
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.